Colinz Laboratories Ltd Stock Price Today (NSE: COLINZ)
Fundamental Score
Colinz Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Colinz Laboratories Ltd share price today is ₹78.43, down 1.96% on NSE/BSE as of 3 August 2026. Colinz Laboratories Ltd (COLINZ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹9.81 (Cr). The 52-week high for COLINZ share price is ₹87.91 and the 52-week low is ₹36.11. At a P/E ratio of 19.23x, COLINZ is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 5.23% and a debt-to-equity ratio of 0.04.
Colinz Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Colinz Laboratories Ltd share price chart: -4.56% return over the past month. 52-week high ₹87.91, 52-week low ₹36.11.
Colinz Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹81.76 | ₹81.76 | ₹78.10 | ₹78.43 | 556.00 (Cr) | |
| ₹82.00 | ₹83.85 | ₹76.90 | ₹82.00 | 7.50K (Cr) | |
| ₹78.00 | ₹82.00 | ₹74.86 | ₹80.00 | 4.82K (Cr) | |
| ₹83.36 | ₹83.36 | ₹78.80 | ₹78.80 | 660.00 (Cr) | |
| ₹83.50 | ₹85.79 | ₹78.55 | ₹82.94 | 2.53K (Cr) | |
| ₹78.50 | ₹82.57 | ₹75.50 | ₹82.57 | 12.16K (Cr) | |
| ₹80.98 | ₹80.98 | ₹76.47 | ₹78.64 | 3.10K (Cr) | |
| ₹77.50 | ₹82.49 | ₹76.20 | ₹80.49 | 394.00 (Cr) | |
| ₹83.50 | ₹83.80 | ₹81.40 | ₹82.00 | 1.91K (Cr) | |
| ₹78.04 | ₹81.94 | ₹77.00 | ₹79.95 | 691.00 (Cr) |
Colinz Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹81.76 | ₹81.76 | ₹78.10 | ₹78.43 | -4.07% | |
| ₹87.44 | ₹87.44 | ₹63.18 | ₹82.00 | -6.22% | |
| ₹56.14 | ₹83.28 | ₹53.11 | ₹83.28 | +48.34% | |
| ₹46.10 | ₹53.47 | ₹42.00 | ₹53.47 | +15.99% | |
| ₹44.49 | ₹49.16 | ₹42.00 | ₹46.10 | +3.62% | |
| ₹46.29 | ₹47.95 | ₹39.31 | ₹44.50 | -3.87% | |
| ₹80.00 | ₹80.00 | ₹45.00 | ₹47.29 | -40.89% | |
| ₹62.69 | ₹87.91 | ₹45.00 | ₹79.01 | +26.03% | |
| ₹39.00 | ₹55.50 | ₹37.21 | ₹53.63 | +37.51% | |
| ₹45.25 | ₹47.50 | ₹36.11 | ₹40.89 | -9.64% | |
| ₹43.20 | ₹46.00 | ₹37.56 | ₹41.53 | -3.87% | |
| ₹41.75 | ₹46.40 | ₹38.13 | ₹41.30 | -1.08% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Micro-cap pharma play is too illiquid and expensive for the risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Colinz Laboratories' share price was The stock traded between and during that day's session.
CORE STORY (THE REAL GAME)
Colinz is a micro-cap pharma company attempting to transition from generics to higher-value specialty formulations in gynecology, cardiology, and gastroenterology. The market views it as a generics player with optionality in higher-margin segments.
- Pharma sector getting funding push
- Low debt provides some downside protection
- Optionality in specialty formulations
- Significant order win in specialty segment
- Successful product launch
- Acquisition by a larger player
- Micro-cap = extreme liquidity risk
- Negative sales CAGR
- High P/E ratio
No FII/DII activity. Promoter holding steady at 66.0%.
India's pharma industry is aiming for innovation-driven growth.
Profit not reliably converting to cash; Free Cash Flow 5Y: ₹2.15 Cr
Colinz needs to demonstrate a clear path to profitability in specialty formulations to justify its valuation. Without it, the stock is dead money.
Primary Thesis Risk
Illiquidity will kill you.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Colinz Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Colinz Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of COLINZ across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Attractive Valuation (P/E: 19.23 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (20.69%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (34.53% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (19.42% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.80x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (50.60%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (5.23%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.20%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-0.07% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Colinz Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Colinz Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Colinz Laboratories LtdColinz Laborato...Selected✓ COLINZ • 531210 | 29.2/100 | ₹78.43₹78 | ₹9.81₹9.81 | 19.23Average 19.2 Average | 5.23%Poor 5.23% Poor | 7.20%Poor 7.20% Poor | 0.04Excellent 0.0 Excellent | 19.42%Excellent 19.42% Excellent | -0.07%Poor -0.07% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Colinz Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for COLINZ — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹1.97 | ₹53.63 | 27.2x |
| FY 2024 | ₹1.93 | ₹69.76 | 36.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Colinz Laboratories Ltd Quarterly Performance
Latest quarterly metrics for COLINZ — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
20.69%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
13.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-0.07%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
19.42%
Compounded annual net profit growth over 5 years
Colinz Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for COLINZ — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Colinz Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Colinz Laboratories Ltd (COLINZ) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Colinz Laboratories Ltd
About COLINZ (Colinz Laboratories Ltd)
Colinz Laboratories Ltd is a pioneering force in the pharmaceutical landscape, dedicated to the research, development, and distribution of innovative healthcare solutions. With a s...teadfast commitment to improving patient outcomes, COLINZ specializes in crafting high-quality pharmaceutical formulations designed to address a wide spectrum of medical needs. Our state-of-the-art facilities and rigorous quality control measures ensure that every product meets the highest industry standards, providing reliable and effective treatments for diverse patient populations. COLINZ is driven by a passion for scientific advancement and a deep understanding of the evolving healthcare landscape, positioning us as a trusted partner for healthcare professionals and patients alike. COLINZ possesses a comprehensive portfolio encompassing a diverse array of pharmaceutical formulations, catering to various therapeutic areas. From conventional dosage forms such as tablets, capsules, and liquids to specialized delivery systems like injectables and topical ointments, we strive to provide versatile treatment options tailored to individual patient needs. COLINZ is deeply committed to providing comprehensive and effective healthcare solutions. Our strategically focused product lines encompass key therapeutic areas, including women's health, cardiovascular care, and gastrointestinal disorders. Our targeted approach allows us to leverage our expertise and resources to deliver specialized treatments that address the unique challenges within these critical healthcare domains. COLINZ is dedicated to pushing the boundaries of pharmaceutical innovation and improving the lives of patients through groundbreaking therapies. Our comprehensive range of allopathic products includes specialized oncology medications, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate and doxorubicin. Our dedication to research and development enables us to bring cutting-edge treatments to market, empowering healthcare professionals with the tools they need to combat serious illnesses. COLINZ is more than just a pharmaceutical company; we are a partner in health, committed to making a tangible difference in the lives of patients around the world.
Company Details
Key Leadership
Latest News
COLINZ Share Price: Frequently Asked Questions
What is the current share price of Colinz Laboratories Ltd?
Colinz Laboratories Ltd (COLINZ) trades at ₹78.43 on NSE and BSE. Market cap ₹9.81 (Cr). Educational data only.
What is the P/E ratio of Colinz Laboratories Ltd?
Colinz Laboratories Ltd has a P/E of 19.23x vs industry average 34.89x.
What is the Bull Run score for Colinz Laboratories Ltd?
Colinz Laboratories Ltd has a Bull Run score of 29.2/100 based on 25+ financial parameters.
Does Colinz Laboratories Ltd pay dividends?
Colinz Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Colinz Laboratories Ltd?
Colinz Laboratories Ltd has ROE of 5.23%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Colinz Laboratories Ltd?
Colinz Laboratories Ltd has debt-to-equity of 0.04.
Is Colinz Laboratories Ltd a good investment?
Bull Run gives Colinz Laboratories Ltd a score of 29.2/100. This is not investment advice — consult a SEBI-registered advisor.